SHINE Technologies has completed a $70 million funding round — the largest investment deal of the year so far in Wisconsin.
The Janesville-based company is developing fusion technologies for applications in various industries, including health care, aerospace and more. Ultimately, SHINE aims to achieve fusion energy generation in the final phase of its four-part business development strategy.
It’s currently advancing the second phase of that plan, which involves producing medical isotopes for cancer treatment. SHINE’s Cassiopeia lutetium-177 production facility is expected to come online by the end of the year, according to yesterday’s release. Lu-177 is a radioactive material used to kill cancer cells through targeted therapies.
;
